Robert P Webb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1558838/publications.pdf

Version: 2024-02-01

10	272	1307594	1372567
10	272		10
papers	citations	h-index	g-index
10	10	10	217
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Development of an o-pthalaldehyde (OPA) assay to measure protein content in Ricin Vaccine E. coli (RVEcâ,,¢). Vaccine, 2021, 39, 564-570.	3.8	1
2	Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function. Toxins, 2020, 12, 611.	3.4	11
3	Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF). Toxicon, 2020, 176, 67-76.	1.6	7
4	Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins. Cell Reports, 2020, 30, 2526-2539.e6.	6.4	24
5	A matrix-focused structure-activity and binding site flexibility study of quinolinol inhibitors of botulinum neurotoxin serotype A. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 675-678.	2.2	10
6	Utilizing Ayurvedic literature for the identification of novel phytochemical inhibitors of botulinum neurotoxin A. Journal of Ethnopharmacology, 2017, 197, 211-217.	4.1	2
7	Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Toxins, 2017, 9, 269.	3.4	33
8	A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model. PLoS ONE, 2012, 7, e29941.	2.5	77
9	Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine, 2009, 27, 4490-4497.	3.8	53
10	Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine, 2007, 25, 4273-4282.	3.8	54